Sorrento Therapeutics, Inc.
Sorrento Therapeutics, Inc., a leading biopharmaceutical company headquartered in the United States, focuses on the development of innovative therapies for cancer and autoimmune diseases. Founded in 2006, Sorrento has made significant strides in the biotechnology sector, particularly in the fields of immunotherapy and antibody development. The company is renowned for its proprietary antibody platform, which includes unique products such as the COVID-19 therapeutic candidate, COVI-MSC, and various cancer treatment modalities. Sorrento's commitment to advancing healthcare solutions has positioned it as a notable player in the biopharmaceutical industry, with a robust pipeline aimed at addressing unmet medical needs. With operations extending across major regions, Sorrento Therapeutics continues to drive innovation and improve patient outcomes globally.
DitchCarbon Score
How does Sorrento Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sorrento Therapeutics, Inc.'s score of 20 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sorrento Therapeutics, Inc.'s reported carbon emissions
Sorrento Therapeutics, Inc., headquartered in the US, currently does not have available carbon emissions data for recent years, as no specific emissions figures have been provided. Consequently, there are no reported Scope 1, 2, or 3 emissions figures to analyse. In the absence of concrete emissions data, it is important to note that Sorrento Therapeutics has not outlined any specific reduction targets or climate commitments. This lack of publicly available information may reflect a broader industry context where many companies are still developing their sustainability strategies and emissions reporting frameworks. As the focus on climate action intensifies, it will be crucial for Sorrento Therapeutics to establish clear climate commitments and reduction initiatives to align with industry standards and stakeholder expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sorrento Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
